Literature DB >> 6690004

A prospective study of the changes in immune status following radiotherapy for Hodgkin's disease.

R E van Rijswijk, J P Sybesma, L Kater.   

Abstract

In a prospective study, immune status was measured in 23 previously untreated patients with Hodgkin's disease Stage I-IIIA. Assessments of immunologic capacity were performed at diagnosis and repeated after staging laparotomy and after radiotherapy. The immune status was measured using delayed-type hypersensitivity tests to common recall antigens, the number of T- and B-lymphocytes in the peripheral blood, in vitro lymphocyte responsiveness to mitogens, antigens, and allogeneic lymphocytes, and serum levels of immunoglobulins. Skin reactivity was not significantly affected by either the staging laparotomy with splenectomy or the radiotherapy. Absolute T-lymphocyte count increased after splenectomy (P less than 0.025) and decreased after radiotherapy (P less than 0.005 compared to postsplenectomy values). In vitro lymphocyte responsiveness after splenectomy was comparable to the initial presenting level and diminished after radiotherapy (P less than 0.005). Serum levels of IgM were lowered after radiotherapy (P less than 0.05) while the fall was not significant after splenectomy. Three months after radiotherapy, lowest mean T-cells percentages were noted, but the responses to mitogens were significantly higher than those obtained immediately after treatment (P less than 0.01). While the reduction in the proportion of the T-lymphocytes persisted for 18 months, the mean lymphocyte responsiveness to mitogens, antigens, and allogeneic lymphocytes increased on follow-up. Apart from a severe impairment of the immune status following radiotherapy, this study also shows the existence of significant repair mechanisms during the follow-up period.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690004     DOI: 10.1002/1097-0142(19840101)53:1<62::aid-cncr2820530112>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.

Authors:  A J Swerdlow; A J Douglas; G V Hudson; B V Hudson; M H Bennett; K A MacLennan
Journal:  BMJ       Date:  1992-05-02

2.  Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer.

Authors:  Mehrdad Talebian Yazdi; Mink S Schinkelshoek; Nikki M Loof; Christian Taube; Pieter S Hiemstra; Marij J P Welters; Sjoerd H van der Burg
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

3.  Mutagenesis after cancer therapy.

Authors:  K T Kelsey; M Caggana; P M Mauch; C N Coleman; J R Clark; H L Liber
Journal:  Environ Health Perspect       Date:  1993-10       Impact factor: 9.031

4.  Hodgkin's disease: subsequent primary cancers in relation to treatment.

Authors:  P Prior; D J Pope
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

5.  Are there overlapping clinical features between thoracic radiotherapy side effects and covid-19 pneumonia? Radiation pneumonitis outside the radiation ports: Three case reports.

Authors:  Grazia Lazzari; Elda Chiara Resta; Michelle Magli; Ernesto D'Ettorre; Giovanni Silvano
Journal:  Clin Transl Radiat Oncol       Date:  2020-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.